The use of mirabegron in neurogenic bladder: a systematic review.
Antimuscarinics
Mirabegron
Neurogenic bladder
Urodynamics
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
04
10
2019
accepted:
25
11
2019
pubmed:
6
12
2019
medline:
27
5
2021
entrez:
6
12
2019
Statut:
ppublish
Résumé
To evaluate the use of mirabegron in patients with neurogenic bladder. A systematic review of the literature was conducted using four databases (Medline via PubMed, Scopus, Cochrane, and EMBASE). Articles evaluating mirabegron in neurogenic bladder patients were collected, and assessment of the drug's efficacy was reviewed according to clinical and urodynamic parameters. Seven studies were selected and a total of 302 patients with NB were evaluated, ranging from 15 to 66 patients per study. All of the patients had received antimuscarinics as a previous treatment modality. Mirabegron was used as a second-line treatment after antimuscarinics lacked efficacy or caused adverse effects. The duration of the treatments ranged from 4 to 12 weeks. Reported in two studies each, bladder compliance and maximal cystometric capacity were the most commonly improved urodynamic parameters. In the majority of the studies, positive outcomes were reported for clinical scores. Additionally, analysis of the IPSS subscores revealed an improvement of storage symptoms as opposed to voiding symptoms. In all of the studies, mirabegron was well tolerated. Mirabegron appears to be an effective treatment in the management of neurogenic bladder unresponsive to antimuscarinics, particularly in patients presenting with storage symptoms. There is still no evidence concerning the use of mirabegron as a first-line therapy for neurogenic bladder.
Identifiants
pubmed: 31802206
doi: 10.1007/s00345-019-03040-x
pii: 10.1007/s00345-019-03040-x
doi:
Substances chimiques
Acetanilides
0
Adrenergic beta-3 Receptor Agonists
0
Thiazoles
0
mirabegron
MVR3JL3B2V
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2435-2442Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Manack A, Motsko SP, Haag-Molkenteller C et al (2013) Epidemiology and Healthcare Utilization of Neurogenic Bladder Patients in a US Claims Database. Neurourol Urodyn 32:215–223. https://doi.org/10.1002/nau
doi: 10.1002/nau
Oh SJ, Shin HI, Paik NJ et al (2006) Depressive symptoms of patients using clean intermittent catheterization for neurogenic bladder secondary to spinal cord injury. Spinal Cord 44:757–762. https://doi.org/10.1038/sj.sc.3101903
doi: 10.1038/sj.sc.3101903
pubmed: 16432529
Oh SJ, Ku JH, Jeon HG et al (2004) Health-related quality of life of patients using clean intermittent catheterization for neurogenic bladder secondary to spinal cord injury. Urology. https://doi.org/10.1016/j.urology.2004.09.032
doi: 10.1016/j.urology.2004.09.032
pubmed: 15533487
Lawerson A, Wyndaele JJ, Vlachonikolis I et al (2001) Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology 20:138–143
doi: 10.1159/000054774
Ginsberg D (2013) The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care 19:191–196
Cameron AP (2010) Pharmacologic therapy for the neurogenic bladder. Urol Clin NA 37:495–506. https://doi.org/10.1016/j.ucl.2010.06.004
doi: 10.1016/j.ucl.2010.06.004
Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M (2012) Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol 62:816–830. https://doi.org/10.1016/j.eururo.2012.02.036
doi: 10.1016/j.eururo.2012.02.036
pubmed: 22397851
Vouri SM, Kebodeaux CD, Stranges PM, Teshome BF (2017) Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis. Arch Gerontol Geriatr 69:77–96. https://doi.org/10.1016/j.archger.2016.11.006
doi: 10.1016/j.archger.2016.11.006
pubmed: 27889591
Kim A, Lee KS, Jung R et al (2017) Health related quality of life in patients with side-effects after antimuscarinic treatment for overactive bladder. LUTS Low Urin Tract Symptoms 9:171–175. https://doi.org/10.1111/luts.12132
doi: 10.1111/luts.12132
pubmed: 27291463
Engeler DS, Meyer D, Abt D et al (2015) Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series. BMC Urol 15:4–9. https://doi.org/10.1186/s12894-015-0102-x
doi: 10.1186/s12894-015-0102-x
Herschorn S, Gajewski J, Ethans K et al (2011) Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a Randomized, double-blind trial. J Urol 185:2229–2235. https://doi.org/10.1016/j.juro.2011.02.004
doi: 10.1016/j.juro.2011.02.004
pubmed: 21497851
Korstanje C, Suzuki M, Yuno K et al (2017) Translational science approach for assessment of cardiovascular effects and proarrhythmogenic potential of the beta-3 adrenergic agonist mirabegron. J Pharmacol Toxicol Methods 87:74–81. https://doi.org/10.1016/j.vascn.2017.04.008
doi: 10.1016/j.vascn.2017.04.008
pubmed: 28434969
Rosa GM, Baccino D, Valbusa A et al (2018) Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder. Expert Opin Drug Saf 17:487–497. https://doi.org/10.1080/14740338.2018.1453496
doi: 10.1080/14740338.2018.1453496
pubmed: 29542337
Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. https://doi.org/10.1186/2046-4053-4-1
doi: 10.1186/2046-4053-4-1
pubmed: 26693720
pmcid: 4688988
Park JS, Lee YS, Lee CN et al (2018) Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. World J Urol. https://doi.org/10.1007/s00345-018-2576-0
doi: 10.1007/s00345-018-2576-0
pubmed: 30511212
Zachariou A, Filiponi M, Baltogiannis D et al (2017) Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. Can J Urol 24:9107–9113
pubmed: 29260636
Welk B, Hickling D, McKibbon M et al (2018) A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn 37:2810–2817. https://doi.org/10.1002/nau.23774
doi: 10.1002/nau.23774
pubmed: 30168626
Wöllner J, Pannek J (2016) Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord 54:78–82. https://doi.org/10.1038/sc.2015.195
doi: 10.1038/sc.2015.195
pubmed: 26503222
Krhut J, Borovička V, Bílková K et al (2018) Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn 37:2226–2233. https://doi.org/10.1002/nau.23566
doi: 10.1002/nau.23566
pubmed: 29603781
Chen SF, Kuo HC (2019) Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. LUTS Low Urin Tract Symptoms 11:O53–O58. https://doi.org/10.1111/luts.12215
doi: 10.1111/luts.12215
pubmed: 29380517
Matsuo T, Miyata Y, Nakamura T et al (2019) Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy. LUTS Low Urin Tract Symptoms 11:O65–O70. https://doi.org/10.1111/luts.12218
doi: 10.1111/luts.12218
pubmed: 29473309
Robinson D, Thiagamoorthy G, Cardozo L (2016) A drug safety evaluation of mirabegron in the management of overactive bladder. Expert Opin Drug Saf 15:689–696. https://doi.org/10.1517/14740338.2016.1165663
doi: 10.1517/14740338.2016.1165663
pubmed: 26980445